Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2015

  • ID: 3455193
  • Company Profile
  • 102 pages
  • Global Markets Direct
1 of 4
‘Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the Sumitomo Dainippon Pharma Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sumitomo Dainippon Pharma Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:

- The report provides brief overview of Sumitomo Dainippon Pharma Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Sumitomo Dainippon Pharma Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Sumitomo Dainippon Pharma Co., Ltd.’s pipeline products

Reasons to buy:

- Evaluate Sumitomo Dainippon Pharma Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Sumitomo Dainippon Pharma Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Sumitomo Dainippon Pharma Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Sumitomo Dainippon Pharma Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sumitomo Dainippon Pharma Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Sumitomo Dainippon Pharma Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Sumitomo Dainippon Pharma Co., Ltd. Snapshot

Sumitomo Dainippon Pharma Co., Ltd. Overview

Key Information

Key Facts

Sumitomo Dainippon Pharma Co., Ltd. - Research and Development Overview

Key Therapeutic Areas

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products Glance

Sumitomo Dainippon Pharma Co., Ltd. - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

Sumitomo Dainippon Pharma Co., Ltd. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Sumitomo Dainippon Pharma Co., Ltd. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Sumitomo Dainippon Pharma Co., Ltd. - Drug Profiles

amrubicin hydrochloride

Product Description

Mechanism of Action

R&D Progress

blonanserin

Product Description

Mechanism of Action

R&D Progress

lurasidone hydrochloride

Product Description

Mechanism of Action

R&D Progress

ranirestat

Product Description

Mechanism of Action

R&D Progress

zonisamide

Product Description

Mechanism of Action

R&D Progress

vatiquinone

Product Description

Mechanism of Action

R&D Progress

afacifenacin

Product Description

Mechanism of Action

R&D Progress

DSP-6952

Product Description

Mechanism of Action

R&D Progress

obeticholic acid

Product Description

Mechanism of Action

R&D Progress

DSP-7888

Product Description

Mechanism of Action

R&D Progress

WT-4869

Product Description

Mechanism of Action

R&D Progress

EPI-589

Product Description

Mechanism of Action

R&D Progress

WT-2725

Product Description

Mechanism of Action

R&D Progress

DSP-0011

Product Description

Mechanism of Action

R&D Progress

DSR-6434

Product Description

Mechanism of Action

R&D Progress

DSR-71167

Product Description

Mechanism of Action

R&D Progress

DSR-98776

Product Description

Mechanism of Action

R&D Progress

NEP-28

Product Description

Mechanism of Action

R&D Progress

SM-276001

Product Description

Mechanism of Action

R&D Progress

SM-295291

Product Description

Mechanism of Action

R&D Progress

SM-324405

Product Description

Mechanism of Action

R&D Progress

SM-369926

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Activate Translocator Protein for Anxiety

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Target Ras Signaling Pathway for Cancer

Product Description

Mechanism of Action

R&D Progress

Drug to Inhibit Apoptosis of Macrophages for Metabolic Syndrome

Product Description

Mechanism of Action

R&D Progress

DSR-17759

Product Description

Mechanism of Action

R&D Progress

HLS-001

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit CaMKII for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit mPGES-1 for Inflammation

Product Description

Mechanism of Action

R&D Progress

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Analysis

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Target

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Route of Administration

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Molecule Type

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Mechanism of Action

Sumitomo Dainippon Pharma Co., Ltd. - Recent Pipeline Updates

Sumitomo Dainippon Pharma Co., Ltd. - Dormant Projects

Sumitomo Dainippon Pharma Co., Ltd. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

emapunil

rafabegron

ceftaroline fosamil

DSP-0565

DSP-3025

DSP-7238

DSP-9599

KGA-3235

limaprost

rafabegron

ranirestat

resequinil

rimacalib

SEP-225425

SEP-226332

SEP-227162

SEP-227900

SMP-028

SMP-797

Sumitomo Dainippon Pharma Co., Ltd. - Company Statement

Sumitomo Dainippon Pharma Co., Ltd. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Sumitomo Dainippon Pharma Co., Ltd., Key Information

Sumitomo Dainippon Pharma Co., Ltd., Key Facts

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Indication, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Stage of Development, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Partnered Products in Pipeline, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Out-Licensed Products in Pipeline, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Pre-Registration, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Phase III, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Phase II, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Phase I, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Preclinical, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Discovery, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Target, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Route of Administration, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Molecule Type, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Recent Pipeline Updates, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Dormant Developmental Projects,2015

Sumitomo Dainippon Pharma Co., Ltd. - Discontinued Pipeline Products, 2015

Sumitomo Dainippon Pharma Co., Ltd., Other Locations

Sumitomo Dainippon Pharma Co., Ltd., Subsidiaries

List of Figures

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Indication, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Stage of Development, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Partnered Products in Pipeline, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Out-Licensed Products in Pipeline, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Target, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015

Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll